Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer

IntroductionIn the last decades, the therapeutic decision-making approach to metastatic renal cell cancer (mRCC) has dramatically changed thanks to the introduction in the treatment scenario of, first, anti-angiogenic agents and, afterward, immune-checkpoint inhibitors (ICIs). Immunotherapy is now t...

Full description

Bibliographic Details
Main Authors:	Alessandra Raimondi, Pierangela Sepe, Emma Zattarin, Alessia Mennitto, Marco Stellato, Melanie Claps, Valentina Guadalupi, Elena Verzoni, Filippo de Braud, Giuseppe Procopio
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-08-01
Series:	Frontiers in Oncology
Subjects:	biomarker immunotherapy metastases PD-L1 renal cell carcinoma tumor mutational burden
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2020.01644/full

Similar Items

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)
by: Pierangela Sepe, et al.
Published: (2024-01-01)

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
by: Paolo Grassi, et al.
Published: (2015-04-01)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016-07-01)

Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
by: Sepe P, et al.
Published: (2020-11-01)

Experience with sorafenib in the treatment of advanced renal cell carcinoma
by: Giuseppe Procopio, et al.
Published: (2012-12-01)

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
by: Maite Alvarez, et al.
Published: (2023-12-01)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
by: Doris Helbig, et al.
Published: (2022-11-01)

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy
by: Bottiglieri A, et al.
Published: (2022-10-01)

Treatment of metastatic brain lesion
by: A. M. Zaytsev, et al.
Published: (2015-06-01)

Successful management of in-transit cutaneous squamous cell carcinoma with anti-PD-1 immunotherapy
by: Chris Furkert, et al.
Published: (2023-09-01)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
by: Qitong Chen, et al.
Published: (2020-05-01)

Impact of non-pulmonary visceral metastases in the prognosis and practice of metastatic testicular germ cell tumors
by: Lorena Rossi, et al.
Published: (2016-04-01)

What is the status of immunotherapy in thyroid neoplasms?
by: Alejandro Garcia-Alvarez, et al.
Published: (2022-08-01)

Chemotherapy-associated liver morphological changes in hepatic metastases (CALMCHeM)
by: Matthew C. Pope, et al.
Published: (2023-07-01)

Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma
by: Xu Yang, et al.
Published: (2024-01-01)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
by: Marco Russano, et al.
Published: (2023-02-01)

Intraventricular metastatic melanoma: A rare case report
by: M.S. Cámara Marcos, et al.
Published: (2022-04-01)

The role of immunotherapy in early-stage and metastatic NSCLC
by: Attila Lieber, et al.
Published: (2024-07-01)

A rare case of a gestational and metastatic choriocarcinoma
by: Abderrahim Siati, et al.
Published: (2019-11-01)

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases
by: Takehiro Tozuka, et al.
Published: (2020-09-01)

Case report: Long-term intracranial effect of zimberelimab monotherapy following surgical resection of high PD-L1-expressing brain metastases from NSCLC
by: Weijia Wu, et al.
Published: (2024-05-01)

Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
by: Rui-Yan Wu, et al.
Published: (2023-01-01)

Metastatic lesion of the right atrium with renal cell carcinoma
by: G O Isaev, et al.
Published: (2019-09-01)

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
by: Brooke C. Bloom, et al.
Published: (2019-04-01)

Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma
by: Johanne Seguin, et al.
Published: (2024-02-01)

Lymphoma immunotherapy: current status
by: Roberta eZappasodi, et al.
Published: (2015-09-01)

Surgical treatment of cardiac metastatic melanoma
by: Robert Kwinta, et al.
Published: (2024-08-01)

Immunological barriers to immunotherapy in primary and metastatic breast cancer
by: Mara De Martino, et al.
Published: (2021-06-01)

Metastatic Cutaneous Melanoma: A Rare Entity with a Unique Presentation
by: Manish Pradhan, et al.
Published: (2019-12-01)

Recent Advances in Immunotherapy in Metastatic NSCLC.
by: Pranshu Bansal, et al.
Published: (2016-11-01)

Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience
by: Alessia Mennitto, et al.
Published: (2016-10-01)

Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
by: Rosario Mazzola, et al.
Published: (2020-05-01)

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma
by: Yan Weng, et al.
Published: (2023-09-01)

Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?
by: Magaly Zappa, et al.
Published: (2017-02-01)

Potential predictors of immunotherapy in small cell lung cancer
by: Valeria Skopelidou, et al.
Published: (2023-05-01)

Case report: Local cryoablation combined with pembrolizumab to eliminate lung metastases from ovarian clear cell carcinoma
by: Liangliang Meng, et al.
Published: (2022-11-01)

Systemic Immunotherapy for the Treatment of Brain Metastases
by: Justine V. Cohen, et al.
Published: (2016-03-01)

Tumor lineage-specific immune response in brain metastatic disease: opportunities for targeted immunotherapy regimen?
by: Shiva Najjary, et al.
Published: (2023-04-01)